Welcome to our dedicated page for Seres Therapeutics SEC filings (Ticker: MCRB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading a biotech filing can feel like scanning a clinical protocol—dense tables, unfamiliar endpoints, and pages of risk factors. Seres Therapeutics adds an extra layer of complexity: live-biotherapeutic manufacturing data, royalty math from its Nestlé Health Science collaboration, and trial updates for VOWST and SER-155. If you have ever hunted through a 10-K to see how long MCRB’s cash runway lasts or waited for Form 4 alerts to gauge executive sentiment, you know the challenge.
Stock Titan solves that problem. Our AI engine converts every paragraph of a Seres Therapeutics quarterly earnings report 10-Q filing into plain-English highlights, flags new risk disclosures, and links them to key metrics. For Seres Therapeutics insider trading Form 4 transactions, you receive real-time push notifications, making Seres Therapeutics Form 4 insider transactions real-time easy to act on. Need context? One click shows how this quarter’s R&D burn compares with last year’s.
Inside the filings hub you’ll find every document the company submits to EDGAR—
- 10-K: Our summary spots pipeline timelines and royalty revenue, giving you a Seres Therapeutics annual report 10-K simplified.
- 8-K: Material news like FDA meetings or shelf offerings appear under Seres Therapeutics 8-K material events explained.
- DEF 14A: Quickly locate equity awards in the Seres Therapeutics proxy statement executive compensation.
Whether you’re tracking Seres Therapeutics executive stock transactions Form 4 or need a concise Seres Therapeutics earnings report filing analysis, our platform keeps you ahead with concise explanations, searchable text, and downloadable data. That’s Seres Therapeutics SEC filings explained simply.
Form 4 Overview: President and Director William C. Emerson reported substantial equity transactions related to Rocket Companies, Inc. (RKT) on 06/30/2025. The filing reflects issuance of Class L-1 and Class L-2 common stock following Rocket’s previously announced Up-C structure collapse.
- Securities acquired: 14,134,895 Class L-1 and 14,134,896 Class L-2 shares to the William C. Emerson Trust; plus 1,413,489 Class L-1 and 1,413,490 Class L-2 shares to each of two family trusts (Nicole Christine Emerson 2012 and Sean William Emerson 2012).
- Consideration: Shares were received at a stated price of $0 per footnote (conversion/recapitalisation, not open-market purchase).
- Transfer & conversion restrictions: L-1 shares locked until 06/30/2026; L-2 shares until 06/30/2027. After lock-ups, each converts 1-for-1 into Class A common stock; automatic conversion occurs upon transfer or if voting power threshold falls.
- Prior holdings: Emerson now indirectly owns 28,269,791 Class L shares through his trust and an additional 5,653,958 Class L shares through family trusts. He directly holds 859,204 Class A shares (includes 453,422 unvested RSUs).
- Corporate context: The Up-C Collapse exchanged Rock Holdings Inc. voting shares for Rocket Class L stock at a fixed 56.54 exchange ratio, simplifying capital structure and migrating legacy owners into Rocket’s equity stack.
The transaction is a non-cash internal recapitalisation; no shares were sold. The filing underscores management’s enlarged economic stake and foreshadows future potential dilution of Class A share count once conversion restrictions lift.
On 06/30/2025, Director Michael D. Eisner filed a Form 4 indicating the acquisition of 343 IAC Inc. (ticker: IAC) common share units at $37.34 per share under the company’s Non-Employee Director Deferred Compensation Plan. After the transaction, Eisner’s aggregate beneficial ownership totals 170,711 shares, consisting of 167,349 shares held directly (including those in a grantor trust) and 3,362 share units accrued in the deferred plan. No sales or derivative security transactions were reported, and ownership remains classified as direct. This filing reflects a routine compensation-related share accrual rather than an open-market purchase or a material change in insider positioning.
On July 1, 2025, Seres Therapeutics (MCRB) filed a Form 4 indicating that non-employee director Claire Fraser received a stock option for 6,452 shares of common stock at an exercise price of $10.71. The option expires on July 1, 2035 and vests in four equal quarterly installments beginning October 1, 2025 and ending July 1, 2026, with the final tranche accelerated if the 2026 annual shareholder meeting occurs earlier. Following the grant, Fraser beneficially owns 6,452 derivative securities; no open-market acquisitions or sales of common stock were reported. The transaction is routine director compensation, non-cash in nature, and does not materially affect Seres Therapeutics’ share count or cash position.
FAQ
What is the current stock price of Seres Therapeutics (MCRB)?
What is the market cap of Seres Therapeutics (MCRB)?
What is the core focus of Seres Therapeutics?
How does Seres Therapeutics generate revenue?
What distinguishes Seres Therapeutics from its competitors?
What are some of the key product candidates?
How does the company’s platform work?
What role do strategic partnerships play for Seres Therapeutics?
Why is restoring the microbiome important for patient outcomes?
How does Seres Therapeutics maintain its competitive edge in a complex industry?
